{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:30Z","timestamp":1793830470270,"version":"4.6.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"blue earth diagnostics"},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands such as <jats:sup>18<\/jats:sup>F-rhPSMA-7 are a new class of theranostic agents in clinical development for prostate cancer. We compared preclinical dosimetry and human biodistribution of <jats:sup>18<\/jats:sup>F-rhPSMA-7 with that of single diastereoisomer form, <jats:sup>18<\/jats:sup>F-rhPSMA-7.3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Preclinical dosimetry was performed with SCID-mice sacrificed at multiple timepoints (10\u2013300\u00a0min) post-injection of 25.6\u2009\u00b1\u20093.6\u00a0MBq <jats:sup>18<\/jats:sup>F-rhPSMA-7 or 28.5\u2009\u00b1\u20094.8\u00a0MBq <jats:sup>18<\/jats:sup>F-rhPSMA-7.3 (<jats:italic>n<\/jats:italic>\u2009=\u20093\u20136 mice per timepoint). Heart, lung, liver, spleen, pancreas, fat, stomach, small intestine, large intestine, kidney, muscle, bone, bladder, testicles, tail, and brain tissue were harvested, and urine and blood samples collected. Percentage of injected dose per gram was calculated. Absorbed doses were estimated with OLINDA\/EXM 1.0.<\/jats:p>\n                <jats:p><jats:sup>18<\/jats:sup>F-rhPSMA-7 (<jats:italic>n<\/jats:italic>\u2009=\u200947) and <jats:sup>18<\/jats:sup>F-rhPSMA-7.3 (<jats:italic>n<\/jats:italic>\u2009=\u200933) PET\/CT exams were used to estimate human biodistribution. Mean (range) injected activities were 324 (236\u2013424) MBq versus 345 (235\u2013420) MBq, and acquisition times were 84 (42\u2013166) versus 76 (59\u2013122) minutes for <jats:sup>18<\/jats:sup>F-rhPSMA-7 versus <jats:sup>18<\/jats:sup>F-rhPSMA-7.3, respectively. SUV<jats:sub>mean<\/jats:sub> was determined for background (gluteal muscle), normal organs (salivary glands, blood pool, lung, liver, spleen, pancreas, duodenum, kidney, bladder, bone) and up to three representative tumour lesions. Qualitative analyses assessed image quality, non-specific blood pool activity, and background uptake in bone\/marrow using 3\/4-point scales.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Preclinical dosimetry revealed that at 3.5\u00a0h and 1\u00a0h bladder voiding intervals, the extrapolated total effective doses were 26.6 and 12.2 \u00b5Sv\/MBq for <jats:sup>18<\/jats:sup>F-rhPSMA-7 and 21.7 and 12.8 \u00b5Sv\/MBq for <jats:sup>18<\/jats:sup>F-rhPSMA-7.3 respectively.<\/jats:p>\n                <jats:p>Human biodistribution of both agents was typical of other PSMA-ligands and broadly similar to each other; SUV<jats:sub>mean<\/jats:sub> were 16.9 versus 16.2 (parotid gland), 19.6 versus 19.9 (submandibular gland), 2.0 versus 1.9 (blood pool, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.005), 0.7 versus 0.7 (lungs), 7.0 versus 7.3 (liver), 9.1 versus 8.4 (spleen), 32.4 versus 35.7 (kidney), 2.5 versus 2.8 (pancreas), 10.9 versus 11.0 (duodenum), 1.1 versus 1.3 (bone) and 4.6 versus 2.0 (bladder; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) for <jats:sup>18<\/jats:sup>F-rhPSMA-7 versus <jats:sup>18<\/jats:sup>F-rhPSMA-7.3, respectively. Tumour SUV<jats:sub>mean<\/jats:sub> was higher for <jats:sup>18<\/jats:sup>F-rhPSMA-7.3 (32.5\u2009\u00b1\u200942.7, <jats:italic>n<\/jats:italic>\u2009=\u200963 lesions) than for <jats:sup>18<\/jats:sup>F-rhPSMA-7 (20.0\u2009\u00b1\u200920.2, <jats:italic>n<\/jats:italic>\u2009=\u200989 lesions).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Radiation dosimetry is favourable for both agents. Radiation exposure, assuming a 1\u00a0h voiding interval, is less than 5\u00a0mSv after injection of 370\u00a0MBq. <jats:sup>18<\/jats:sup>F-rhPSMA-7.3 showed significantly lower bladder uptake, and a higher uptake trend in tumours compared with <jats:sup>18<\/jats:sup>F-rhPSMA-7.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-021-00872-w","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:13:54Z","timestamp":1643973234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-4805","authenticated-orcid":false,"given":"Karina","family":"Knorr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Won","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wurzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"D\u2019Alessandria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Herz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Yusufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Nekolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"872_CR1","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256\u201361.","journal-title":"Cancer"},{"key":"872_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528\u201339.","journal-title":"J Cell Biochem"},{"key":"872_CR3","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1073\/pnas.1106383108","volume":"108","author":"MJ Evans","year":"2011","unstructured":"Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108:9578\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"872_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2967\/jnumed.112.104661","volume":"53","author":"SY Cho","year":"2012","unstructured":"Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883\u201391.","journal-title":"J Nucl Med"},{"key":"872_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate Cancer. Mol Imaging Biol. 2015;17:565\u201374.","journal-title":"Mol Imaging Biol"},{"key":"872_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"872_CR7","doi-asserted-by":"publisher","first-page":"702","DOI":"10.2967\/jnumed.119.234609","volume":"61","author":"SW Oh","year":"2019","unstructured":"Oh SW, Wurzer A, Teoh EJ, Oh S, Langbein T, Kronke M, et al. Quantitative and qualitative analyses of biodistribution and PET image quality of novel radiohybrid PSMA, 18F-rhPSMA-7, in patients with prostate cancer. J Nucl Med. 2019;61:702\u20139.","journal-title":"J Nucl Med"},{"key":"872_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2967\/jnumed.119.234914","volume":"61","author":"M Eiber","year":"2019","unstructured":"Eiber M, Kronke M, Wurzer A, Ulbrich L, Jooss L, Maurer T, et al. 18F-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy. J Nucl Med. 2019;61:696\u2013701.","journal-title":"J Nucl Med"},{"key":"872_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2967\/jnumed.119.234906","volume":"61","author":"M Kronke","year":"2019","unstructured":"Kronke M, Wurzer A, Schwamborn K, Ulbrich L, Jooss L, Maurer T, et al. Histologically-confirmed diagnostic efficacy of 18F-rhPSMA-7 positron emission tomography for N-staging of patients with primary high risk prostate cancer. J Nucl Med. 2019;61:710\u20135.","journal-title":"J Nucl Med"},{"key":"872_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13550-020-00740-z","volume":"10","author":"A Wurzer","year":"2020","unstructured":"Wurzer A, Parzinger M, Konrad M, Beck R, G\u00fcnther T, Felber V, et al. Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics. EJNMMI Res. 2020;10:149.","journal-title":"EJNMMI Res"},{"key":"872_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.119.234922","volume":"61","author":"A Wurzer","year":"2019","unstructured":"Wurzer A, DiCarlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, et al. Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA-inhibitors. J Nucl Med. 2019;61:735\u201342.","journal-title":"J Nucl Med"},{"key":"872_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/jps.2600820718","volume":"82","author":"J Yuan","year":"1993","unstructured":"Yuan J. Estimation of variance for AUC in animal studies. J Pharm Sci. 1993;82:761\u20133.","journal-title":"J Pharm Sci"},{"key":"872_CR13","first-page":"713","volume":"14","author":"AS Kirschner","year":"1973","unstructured":"Kirschner AS, Ice RD, Beierwaltes WH. Radiation dosimetry of 131I\u201319-iodocholesterol. J Nucl Med. 1973;14:713\u20137.","journal-title":"J Nucl Med"},{"key":"872_CR14","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"key":"872_CR15","volume-title":"ICRP publication 106, addendum 3 to ICRP publication 53: radiation dose to patients from radiopharmaceuticals","author":"International Commission on Radiological Protection","year":"2007","unstructured":"International Commission on Radiological Protection. ICRP publication 106, addendum 3 to ICRP publication 53: radiation dose to patients from radiopharmaceuticals. Oxford: Pergamon; 2007."},{"key":"872_CR16","doi-asserted-by":"publisher","unstructured":"Tolvanen T, Kalliokoski KK, Malaspina S, Kuisma A, Lahdenpohja S, Postema EJ, et al. Safety, biodistribution and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers. J Nucl Med. 2020. https:\/\/doi.org\/10.2967\/jnumed.120.252114.","DOI":"10.2967\/jnumed.120.252114"},{"key":"872_CR17","doi-asserted-by":"crossref","unstructured":"Heusser T, Mann P, Rank CM, Schafer M, Dimitrakopoulou-Strauss A, Schlemmer HP, et al. Investigation of the halo-artifact in 68Ga-PSMA-11-PET\/MRI. PLoS ONE. 2017;12:e0183329.","DOI":"10.1371\/journal.pone.0183329"},{"key":"872_CR18","doi-asserted-by":"crossref","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324.","DOI":"10.1007\/s00259-017-3670-z"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00872-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-021-00872-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00872-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:27:35Z","timestamp":1643974055000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-021-00872-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1186\/s13550-021-00872-w","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"assertion":[{"value":"2 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preclinical evaluation study was performed in accordance with the German Animal Welfare Act (Deutsches Tierschutzgesetz, approval #55.2-1-54-2532-216-2015). The retrospective analysis was approved by the Local Ethics Committee (permits 290\/18S and 99\/19S).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patient consent was waived by the local Ethics Committee (permits 290\/18S and 99\/19S) given the retrospective nature of the analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patient consent was waived by the local Ethics Committee (permits 290\/18S and 99\/19S) given the retrospective nature of the analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Patent application for rhPSMA (HJW, AW and ME). HJW and ME received funding from the SFB 824 (DFG Sonderforschungsbereich 824, Project B11) from the Deutsche Forschungsgemeinschaft, Bonn, Germany and Blue Earth Diagnostics Limited (licensee for rhPSMA) as part of an academic collaboration. HJW is founder, shareholder and advisor board member of Scintomics GmbH, Fuerstenfeldbruck, Germany. WW is a consultant for Blue Earth Diagnostics Limited. ME reports prior consulting activities for Blue Earth Diagnostics, Progenics Pharmaceuticals, Point Biopharma and Janssen Pharmaceuticals. No other potential conflicts of interest relevant to this article exist.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}